|
Type 2 diabetes treatment
|
|
Udupa, AS [134]
|
Randomized, double- blind placebo-controlled
|
Vitamin E, omega 3 fatty acids ALA 300 mg All of them daily/orally
|
Weight, waist glucose
|
104 with IR
|
5-10 y
|
12 w
|
< HbA1c, weight, waist Better results with omega-3 followed by vitamin E and ALA
|
|
Porasuphatana S [135]
|
Randomized, placebo- controlled
|
ALA 300 mg -1200 mg/d
|
HbA1c, FBG
|
38
|
2.07 ± 0.26
|
24 w
|
<HbA1c, FBG
|
|
De Oliveira AM [136]
|
Randomized, double- blind placebo-controlled
|
ALA 600 mg or Vitamin E 800 mg or ALA 600 mg plus Vitamin E 800 mgr
|
HOMA index, glucose, lipid profile insulin
|
102
| |
16 w
| |
|
Diabetic retinopathy
|
|
Haritoglou C [139]
|
Randomized ,double-blind placebo-controlled
|
ALA 600 mg/daily
|
Development of macular edema
|
232 patients with type 2 and 170 with T1D
| |
86 w
|
no effect
|
|
Nebioso M [140]
|
Randomized not placebo-controlled
|
ALA 400 mg daily plus vitamins and genistein
|
ERG
|
32
|
NA
|
4 w
|
Improvement in ERG
|
|
Diabetic nephropathy
|
|
Borcea V [143]
|
Cross-sectional not placebo-controlled
|
ALA 600 mg/daily/orally
|
Lipid ROOH, HbA1c, urine albumin, α tocopherol
|
107 patients [45 with T1D and 29 with T2D]
|
21.7 ± 11.1 (with ALA); 15.3 ± 10.4 (without ALA)
|
>12 w
|
< ROOH < ROOH/(,α tocopherol/cholesterol The decrease was independent of HbA1c and urine albumin level
|
|
Cicek M [144]
|
Randomized not placebo-controlled
|
ALA 600 mg/ /orally
|
CIN Plasma creatinine, Cystation C
|
79
|
NA
|
Prior coronary angiography
|
No effect in the incidence of CIN, creatinine, Cystatin C pré /pos exam
|
|
Chang JW [145]
|
Randomized placebo-controlled
|
ALA 600 mg/orally
|
Cholesterol, HbA1c C-reactive protein, oxidizedLDL- ADMA
|
50 patients on hemodyalisis treatment
|
NA
|
12 w
|
Decrease the level of ADMA
|
|
Diabetes endothelial dysfunction
|
|
Heinisch BB [147]
|
Randomized, Controlled,double- blind placebo parallel
|
Daily 600 mg of ALA IV
|
Endothelial function endothelium dependent and independent HbA1c, lipid profile
|
30 patients with TD2
|
7 ± 6
|
3 w
|
Improvement in endothelium dependent function
|
|
Diabetic cardiovascular autonomic neuropathy
|
|
Pop-Busui R [150]
|
Prospective, randomized, double- blind, placebo- controlled
|
ALA 600 mg/twice daily Nicotinamide 750 mg/twice daily Allupurinol 300 mg/daily All of them orally
|
Autonomic tests PET F2 urinary isoprostane HbA1c
|
44 patients with T1D with mild/moderate cardiovascular autonomic neuropathy and retinopathy or microalbuminuria
|
27 ± 12
|
2 y
|
No improvement in any analyzed parameter
|
|
Ziegler D [151]
|
Randomized, double- blind, placebo- controlled
|
ALA 800 mg/daily (orally)
|
Heart rate variability HbA1c Autonomic symptoms
|
73 patients with T2D
|
15.3 ± 8.3
|
16 w
|
Improvement on root mean square successive difference and power spectrum in low frequency band No difference in the prevalence of symptoms
|
|
Diabetic polyneuropathy
|
|
ZiegleR D [153] ALADIN I
|
Randomized,double- blind controlled parallel
|
ALA:1200 or 600 or 100 mg/daily (orally)
|
TSS HbA1c
|
328 patients with T2D with symptomatic peripheral neuropathy
|
10.4/12.3
|
3 w
|
Improvement in TSS HbA1c: no difference
|
|
Reljanovic M [154] ALADIN II
|
Prospective randomized,double- blind controlled
|
ALA 1200 mg or 600 mg orally
|
Sensory and motor nerve function
|
299 patients (T1D and T2D) with symptomatic polyneuropathy
|
NA
|
2 y
|
Improvement in electrophysiological tests HbA1c: no difference
|
|
Ziegler D.[155] ALADIN III
|
Prospective randomized, double- blind controlled
|
ALA 600 mg/ IV followed by 1800 mg of ALA or placebo orally
|
TSS NIS
|
516 patients with T2D with symptomatic polyneuropathy
|
11
|
3 w (IV) 24 w (orally)
|
No effect HbA1c:no difference
|
|
Ametov As [157] Sidney I
|
Randomized, double- blind ,parallel controlled, mono-center
|
ALA 600 mg IV
|
TSS
|
120 (T1D and T2D) with DSPN
|
15.1 ± 8.8
|
3
|
Improvement
|
|
Ziegler D [158] Sidney II
|
Randomized, double- blind, parallel controlled, multicenter
|
ALA 600 to 1800 mg/orally
|
TSS
|
181 (T1D and T2D) with DSPN
|
14
|
5
|
Improvement
|
|
Ziegler D [159] Nathan I
|
Randomized, double- blind, parallel controlled, multicenter
|
ALA 600 mg/orally
|
TSS Composite score( NIS–lower limbs plus 7 neurophisiologic tests (NIS-LL+7)
|
460 (T1D and T2D) with DSPN
|
13.3
|
4 years
|
TSS: no improvement NSI-LL+7:improvement
|
|
Ziegler D [160]
|
Meta-analysis
|
ALA 600mg IV
|
TSS, NIS-LL
|
1258
|
132 months
|
3 w
|
Improvement in TSS (papin-prick,touch-pressure), burning,numbness) Improvement in NIS-LL
|
|
Mijnhout GS [161]
|
Meta-analysis
|
ALA orally ( 600 to 1800 mg daily) ALA IV (100 to 1200 mg/daily)
|
TSS
|
653
|
NA
|
3 to 5 w
|
Improvement in TSS but greater than 30% only in intravenously treated patients
|
